{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:55:51Z","timestamp":1789638951059,"version":"4.0.0"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea grant","doi-asserted-by":"crossref","award":["NRF-RS-2020-NR049583 (Center for Proteinopathy)"],"award-info":[{"award-number":["NRF-RS-2020-NR049583 (Center for Proteinopathy)"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-RS-2024-00333784 (J.-M.H.)"],"award-info":[{"award-number":["NRF-RS-2024-00333784 (J.-M.H.)"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Chem Res"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00044-026-03557-y","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:15:24Z","timestamp":1776446124000},"page":"726-756","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Protein kinases as therapeutic targets in Alzheimer\u2019s disease: challenges, insights, and new frontiers"],"prefix":"10.1007","volume":"35","author":[{"given":"Chanwool","family":"Tak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapnil P.","family":"Bhujbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6439-0405","authenticated-orcid":false,"given":"Jung-Mi","family":"Hah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"3557_CR1","first-page":"549","volume":"15","author":"I Shawkatova","year":"2025","unstructured":"Shawkatova I, Javor J. Alzheimer\u2019s disease: Recent developments in pathogenesis, diagnosis, and therapy. Life (Basel). 2025;15:549.","journal-title":"Life (Basel)"},{"key":"3557_CR2","volume":"9","author":"J Cummings","year":"2023","unstructured":"Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F, et al. Alzheimer\u2019s disease drug development pipeline: 2023. Alzheimers Dement. 2023;9:e12385.","journal-title":"Alzheimers Dement"},{"key":"3557_CR3","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med. 2016;8:595\u2013608.","journal-title":"EMBO Mol Med"},{"key":"3557_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. 4. Acta Neuropathol. 1991;82:239\u201359.","journal-title":"4. Acta Neuropathol"},{"key":"3557_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.113945","volume":"177","author":"K Mullane","year":"2020","unstructured":"Mullane K, Williams M. Alzheimer\u2019s disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?. Biochem Pharmacol. 2020;177:113945.","journal-title":"Biochem Pharmacol"},{"key":"3557_CR6","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"JM Long","year":"2019","unstructured":"Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179:312\u201339.","journal-title":"Cell"},{"key":"3557_CR7","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1126\/science.1075762","volume":"298","author":"G Manning","year":"2002","unstructured":"Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298:1912\u201334.","journal-title":"Science"},{"key":"3557_CR8","first-page":"46","volume":"7","author":"M Llorens-Mar\u00edtin","year":"2014","unstructured":"Llorens-Mar\u00edtin M, Jurado J, Hern\u00e1ndez F, \u00c1vila J. GSK-3\u03b2, a pivotal kinase in Alzheimer disease. Front Mol Neurosci. 2014;7:46.","journal-title":"Front Mol Neurosci"},{"key":"3557_CR9","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1242\/jcs.147553","volume":"127","author":"K Shah","year":"2014","unstructured":"Shah K, Lahiri DK. Cdk5 activity in the brain\u2013multiple paths of regulation. J Cell Sci. 2014;127:2391\u2013400.","journal-title":"J Cell Sci"},{"key":"3557_CR10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nrd773","volume":"1","author":"P Cohen","year":"2002","unstructured":"Cohen P. Protein kinases\u2014the major drug targets of the twenty-first century?. Nat Rev Drug Discov. 2002;1:309\u201315.","journal-title":"Nat Rev Drug Discov"},{"key":"3557_CR11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3892\/ijmm.2017.3036","volume":"40","author":"F Ardito","year":"2017","unstructured":"Ardito F, Giuliani M, Perrone D, Troiano G, Lo Muzio LJ. The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy. Int J Mol Med. 2017;40:271\u201380.","journal-title":"Int J Mol Med"},{"key":"3557_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nrn.2015.1","volume":"17","author":"Y Wang","year":"2016","unstructured":"Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci. 2016;17:22\u201335.","journal-title":"Nat Rev Neurosci"},{"key":"3557_CR13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.molmed.2009.01.003","volume":"15","author":"DP Hanger","year":"2009","unstructured":"Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med. 2009;15:112\u20139.","journal-title":"Trends Mol Med"},{"key":"3557_CR14","doi-asserted-by":"publisher","first-page":"25457","DOI":"10.1074\/jbc.M603469200","volume":"281","author":"F Plattner","year":"2006","unstructured":"Plattner F, Angelo M, Giese KP. The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J Biol Chem. 2006;281:25457\u201365.","journal-title":"J Biol Chem"},{"key":"3557_CR15","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1111\/j.1471-4159.2006.04059.x","volume":"98","author":"S Sato","year":"2006","unstructured":"Sato S, Cerny RL, Buescher JL, Ikezu TJ. Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation. J Neurochem. 2006;98:1573\u201384.","journal-title":"J Neurochem"},{"key":"3557_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/alzrt238","volume":"6","author":"HB Nygaard","year":"2014","unstructured":"Nygaard HB, van Dyck CH, Strittmatter SM. therapy. Fyn kinase inhibition as a novel therapy for Alzheimer\u2019s disease. Alzheimers Res Ther. 2014;6:8.","journal-title":"Alzheimers Res Ther"},{"key":"3557_CR17","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/ana.410300410","volume":"30","author":"RD Terry","year":"1991","unstructured":"Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer\u2019s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572\u201380.","journal-title":"Ann Neurol"},{"key":"3557_CR18","doi-asserted-by":"publisher","first-page":"5721","DOI":"10.1242\/jcs.01558","volume":"117","author":"GV Johnson","year":"2004","unstructured":"Johnson GV, Stoothoff WH. Tau phosphorylation in neuronal cell function and dysfunction. J Cell Sci. 2004;117:5721\u20139.","journal-title":"J Cell Sci"},{"key":"3557_CR19","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/s41593-018-0242-x","volume":"21","author":"S Hickman","year":"2018","unstructured":"Hickman S, Izzy S, Sen P, Morsett L, El Khoury J. Microglia in neurodegeneration. Nat Neurosci. 2018;21:1359\u201369.","journal-title":"Nat Neurosci"},{"key":"3557_CR20","doi-asserted-by":"crossref","unstructured":"Birks J Cholinesterase inhibitors for Alzheimer\u2019s disease. Cochrane Database Syst Rev. 2006:CD005593","DOI":"10.1002\/14651858.CD005593"},{"key":"3557_CR21","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/13543784.2017.1323868","volume":"26","author":"D Mehta","year":"2017","unstructured":"Mehta D, Jackson R, Paul G, Shi J, Sabbagh M. Why do trials for Alzheimer\u2019s disease drugs keep failing? A discontinued drug perspective for 2010-2015. Expert Opin Investig Drugs. 2017;26:735\u20139.","journal-title":"Expert Opin Investig Drugs"},{"key":"3557_CR22","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/nrd2999","volume":"8","author":"LK Chico","year":"2009","unstructured":"Chico LK, Van Eldik LJ, Watterson DM. Targeting protein kinases in central nervous system disorders. Nat Rev Drug Discov. 2009;8:892\u2013909.","journal-title":"Nat Rev Drug Discov"},{"key":"3557_CR23","first-page":"455","volume":"26","author":"V Waetzig","year":"2005","unstructured":"Waetzig V, Herdegen T. Context-specific inhibition of JNKs: overcoming the dilemma of protection and damage. Trends Pharmacol Sci. 2005;26:455\u201361.","journal-title":"Trends Pharmacol Sci"},{"key":"3557_CR24","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1128\/MMBR.00025-06","volume":"70","author":"MA Bogoyevitch","year":"2006","unstructured":"Bogoyevitch MA, Kobe BJ. Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. Microbiol Mol Biol Rev. 2006;70:1061\u201395.","journal-title":"Microbiol Mol Biol Rev"},{"key":"3557_CR25","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1002\/j.1460-2075.1996.tb00636.x","volume":"15","author":"S Gupta","year":"1996","unstructured":"Gupta S, Barrett T, Whitmarsh A, Cavanagh J, Sluss H, Derijard B, et al. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 1996;15:2760\u201370.","journal-title":"EMBO J"},{"key":"3557_CR26","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.tiv.2017.02.015","volume":"41","author":"VPK Muthaiah","year":"2017","unstructured":"Muthaiah VPK, Michael FM, Palaniappan T, Rajan SS, Chandrasekar K, Venkatachalam S. JNK1 and JNK3 play a significant role in both neuronal apoptosis and necrosis. Evaluation based on in vitro approach using tert-butylhydroperoxide induced oxidative stress in neuro-2A cells and perturbation through 3-aminobenzamide. Toxicol In Vitro. 2017;41:168\u201378.","journal-title":"Toxicol In Vitro"},{"key":"3557_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1177\/153331750201700209","volume":"17","author":"H Okazawa","year":"2002","unstructured":"Okazawa H, Estus S. The JNK\/c-Jun cascade and Alzheimer\u2019s disease. Am J Alzheimers Dis Other Demen. 2002;17:79\u201388.","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"3557_CR28","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.1074\/jbc.M108357200","volume":"277","author":"MH Scheinfeld","year":"2002","unstructured":"Scheinfeld MH, Roncarati R, Vito P, Lopez PA, Abdallah M, D\u2019Adamio LJ. Jun NH2-terminal kinase (JNK) interacting protein 1 (JIP1) binds the cytoplasmic domain of the Alzheimer\u2019s \u03b2-amyloid precursor protein (APP). J Biol Chem. 2002;277:3767\u201375.","journal-title":"J Biol Chem"},{"key":"3557_CR29","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.nbd.2008.12.014","volume":"33","author":"A Colombo","year":"2009","unstructured":"Colombo A, Bastone A, Ploia C, Sclip A, Salmona M, Forloni G, et al. JNK regulates APP cleavage and degradation in a model of Alzheimer\u2019s disease. Neurobiol Dis. 2009;33:518\u201325.","journal-title":"Neurobiol Dis"},{"key":"3557_CR30","doi-asserted-by":"publisher","first-page":"5533","DOI":"10.1523\/JNEUROSCI.4883-04.2005","volume":"25","author":"WT Kimberly","year":"2005","unstructured":"Kimberly WT, Zheng JB, Town T, Flavell RA, Selkoe DJ. Physiological regulation of the \u03b2-amyloid precursor protein signaling domain by c-Jun N-terminal kinase JNK3 during neuronal differentiation. J Neurosci. 2005;25:5533\u201343.","journal-title":"J Neurosci"},{"key":"3557_CR31","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.neuron.2012.06.024","volume":"75","author":"SO Yoon","year":"2012","unstructured":"Yoon SO, Park DJ, Ryu JC, Ozer HG, Tep C, Shin YJ, et al. JNK3 perpetuates metabolic stress induced by A\u03b2 peptides. Neuron. 2012;75:824\u201337.","journal-title":"Neuron"},{"key":"3557_CR32","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1046\/j.1471-4159.1997.68041736.x","volume":"68","author":"CH Reynolds","year":"1997","unstructured":"Reynolds CH, Utton MA, Gibb GM, Yates A, Anderton B. Stress-Activated Protein Kinase\/c-Jun N-Terminal Kinase Phosphorylates \u03c4 Protein. J Neurochem. 1997;68:1736\u201344.","journal-title":"J Neurochem"},{"key":"3557_CR33","doi-asserted-by":"publisher","first-page":"9677","DOI":"10.3390\/ijms21249677","volume":"21","author":"SC Hepp Rehfeldt","year":"2020","unstructured":"Hepp Rehfeldt SC, Majolo F, Goettert MI, Laufer SJ. c-Jun N-terminal kinase inhibitors as potential leads for new therapeutics for Alzheimer\u2019s diseases. Int J Mol Sci. 2020;21:9677.","journal-title":"Int J Mol Sci"},{"key":"3557_CR34","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1007\/s12272-025-01566-w","volume":"48","author":"SP Bhujbal","year":"2025","unstructured":"Bhujbal SP, Hah J-M. Advances in JNK inhibitor development: therapeutic prospects in neurodegenerative diseases and fibrosis. Arch Pharm Res. 2025;48:858\u201386.","journal-title":"Arch Pharm Res"},{"key":"3557_CR35","doi-asserted-by":"publisher","first-page":"a021857","DOI":"10.1101\/cshperspect.a021857","volume":"6","author":"ER Stanley","year":"2014","unstructured":"Stanley ER, Chitu VJ. CSF-1 receptor signaling in myeloid cells. Cold Spring Harb Perspect Biol. 2014;6:a021857.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"3557_CR36","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.neuron.2014.02.040","volume":"82","author":"MR Elmore","year":"2014","unstructured":"Elmore MR, Najafi AR, Koike MA, Dagher NN, Spangenberg EE, Rice RA, et al. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron. 2014;82:380\u201397.","journal-title":"Neuron"},{"key":"3557_CR37","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ydbio.2012.03.026","volume":"367","author":"S Nandi","year":"2012","unstructured":"Nandi S, Gokhan S, Dai X-M, Wei S, Enikolopov G, Lin H, et al. The CSF-1 receptor ligands IL-34 and CSF-1 exhibit distinct developmental brain expression patterns and regulate neural progenitor cell maintenance and maturation. Dev Biol. 2012;367:100\u201313.","journal-title":"Dev Biol"},{"key":"3557_CR38","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s10787-022-00958-4","volume":"30","author":"P Tarale","year":"2022","unstructured":"Tarale P, Alam M. Colony-stimulating factor 1 receptor signaling in the central nervous system and the potential of its pharmacological inhibitors to halt the progression of neurological disorders. Inflammopharmacology. 2022;30:821\u201342.","journal-title":"Inflammopharmacology"},{"key":"3557_CR39","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature21029","volume":"541","author":"SA Liddelow","year":"2017","unstructured":"Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481\u20137.","journal-title":"Nature"},{"key":"3557_CR40","doi-asserted-by":"publisher","first-page":"E197","DOI":"10.1073\/pnas.1111098109","volume":"109","author":"O Pascual","year":"2012","unstructured":"Pascual O, Ben Achour S, Rostaing P, Triller A, Bessis A. Microglia activation triggers astrocyte-mediated modulation of excitatory neurotransmission. Proc. Natl. Acad. Sci. U.S.A. 2012;109:E197\u2013E205.","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"3557_CR41","doi-asserted-by":"publisher","first-page":"e091161","DOI":"10.1002\/alz.091161","volume":"20","author":"WD Tamayanti","year":"2024","unstructured":"Tamayanti WD, Lin JR, Ariyanti AD, Chang Y, Cheng HY, Huang CW, et al. Safety of the CSF1R inhibitor EI-1071 in human and its pharmacological effects to reduce neuroinflammation and improve memory function in a mouse model of Alzheimer\u2019s disease. Alzheimers Dement. 2024;20:e091161.","journal-title":"Alzheimers Dement"},{"key":"3557_CR42","doi-asserted-by":"publisher","first-page":"117187","DOI":"10.1016\/j.bcp.2025.117187","volume":"242","author":"L Peng","year":"2025","unstructured":"Peng L, Fang Z, Zhang W, Rao G-W, Zheng Q. Recent advances in colony stimulating factor-1 receptor (CSF1R) inhibitors. Biochem Pharmacol. 2025;242:117187.","journal-title":"Biochem Pharmacol"},{"key":"3557_CR43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/ird3.44","volume":"2","author":"X Zha","year":"2024","unstructured":"Zha X, Hui W, Cheng D, Shi H, Luo Z. Targeting colony-stimulating factor 1 receptor: From therapeutic drugs to diagnostic radiotracers. iRADIOLOGY. 2024;2:35\u201365.","journal-title":"iRADIOLOGY"},{"key":"3557_CR44","doi-asserted-by":"publisher","unstructured":"Mills KA, Du Y, Coughlin JM, Foss CA, Horti AG, Jenkins KR et al. Exploring [11 C] CPPC as a CSF1R-targeted PET imaging marker for early Parkinson\u2019s disease severity. medRxiv. [Preprint]. 2024 https:\/\/doi.org\/10.1101\/2023.05.28.23290647.","DOI":"10.1101\/2023.05.28.23290647"},{"key":"3557_CR45","doi-asserted-by":"publisher","first-page":"351","DOI":"10.62347\/QFGP5253","volume":"14","author":"P Roy","year":"2024","unstructured":"Roy P, Guo Y, Muzik O, Woodcock EA, Jiang HJ, Imaging M. Fully automated radiosynthesis of [18F] FCPPC for imaging microglia with PET. Am J Nucl Med Mol Imaging. 2024;14:351.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"3557_CR46","doi-asserted-by":"publisher","unstructured":"Falchook GS, Liang Y, Harvey RD, Fu S, Weitao Y, Qin Y-R et al. First-in-human phase 1 study of pimicotinib (ABSK021), a CSF-1R inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2023. https:\/\/doi.org\/10.1200\/jco.2023.41.16_suppl.3100.","DOI":"10.1200\/jco.2023.41.16_suppl.3100"},{"key":"3557_CR47","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1080\/14796694.2024.2396227","volume":"22","author":"X Niu","year":"2024","unstructured":"Niu X, Ravi V, Guo Q, Shi H, Zou Q, Shan B. et al. MANEUVER: A Phase III study of pimicotinib to assess efficacy and safety in tenosynovial giant cell tumor patients. Future oncol. 2024;22:507\u2013514.","journal-title":"Future oncol"},{"key":"3557_CR48","doi-asserted-by":"publisher","first-page":"5699","DOI":"10.1021\/acs.jmedchem.3c02366","volume":"67","author":"J Baek","year":"2024","unstructured":"Baek J, Jun J, Kim H, Bae H, Park H, Cho H, et al. Targeting the CSF-1\/CSF-1R Axis: exploring the potential of CSF1R inhibitors in neurodegenerative diseases. J Med Chem. 2024;67:5699\u2013720.","journal-title":"J Med Chem"},{"key":"3557_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116253","volume":"268","author":"J Baek","year":"2024","unstructured":"Baek J, Kim H, Jun J, Kang D, Bae H, Cho H, et al. Discovery of N-(5-amido-2-methylphenyl)-5-methylisoxazole-3-carboxamide as dual CSF-1R\/c-Kit Inhibitors with improved stability and BBB permeability. Eur J Med chem. 2024;268:116253.","journal-title":"Eur J Med chem"},{"key":"3557_CR50","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1242\/jcs.00384","volume":"116","author":"BW Doble","year":"2003","unstructured":"Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci. 2003;116:1175\u201386.","journal-title":"J Cell Sci"},{"key":"3557_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/bj3590001","volume":"359","author":"S Frame","year":"2001","unstructured":"Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J. 2001;359:1\u201316.","journal-title":"Biochem J"},{"key":"3557_CR52","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.1007\/s12035-023-03839-1","volume":"61","author":"RC Sequeira","year":"2024","unstructured":"Sequeira RC, Godad A. Understanding glycogen synthase kinase-3: a novel avenue for Alzheimer\u2019s disease. Mol Neurobiol. 2024;61:4203\u201321.","journal-title":"Mol Neurobiol"},{"key":"3557_CR53","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/189728","volume":"2011","author":"P Salcedo-Tello","year":"2011","unstructured":"Salcedo-Tello P, Ortiz-Matamoros A, Arias C. GSK3 function in the brain during development, neuronal plasticity, and neurodegeneration. Int J Alzheimers Dis. 2011;2011:189728.","journal-title":"Int J Alzheimers Dis"},{"key":"3557_CR54","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1172\/JCI64516","volume":"123","author":"PT Ly","year":"2012","unstructured":"Ly PT, Wu Y, Zou H, Wang R, Zhou W, Kinoshita A, et al. Inhibition of GSK3\u03b2-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J clin Invest. 2012;123:224\u201335.","journal-title":"J clin Invest"},{"key":"3557_CR55","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3390\/cells10020262","volume":"10","author":"I Rippin","year":"2021","unstructured":"Rippin I, Eldar-Finkelman H. Mechanisms and therapeutic implications of GSK-3 in treating neurodegeneration. Cells. 2021;10:262.","journal-title":"Cells"},{"key":"3557_CR56","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/jnr.21850","volume":"87","author":"NE LaPointe","year":"2009","unstructured":"LaPointe NE, Morfini G, Pigino G, Gaisina IN, Kozikowski AP, Binder LI, et al. The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity. J Neurosci Res. 2009;87:440\u201351.","journal-title":"J Neurosci Res"},{"key":"3557_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2020.118664","volume":"1867","author":"E Lauretti","year":"2020","unstructured":"Lauretti E, Dincer O, Pratic\u00f2 D. Glycogen synthase kinase-3 signaling in Alzheimer\u2019s disease. Biochim Biophys Acta Mol Cell Res. 2020;1867:118664.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"3557_CR58","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1074\/jbc.M111.306472","volume":"287","author":"JM Dom\u00ednguez","year":"2012","unstructured":"Dom\u00ednguez JM, Fuertes A, Orozco L, del Monte-Mill\u00e1n M, Delgado E, Medina M. Evidence for irreversible inhibition of glycogen synthase kinase-3\u03b2 by tideglusib. J Biol Chem. 2012;287:893\u2013904.","journal-title":"J Biol Chem"},{"key":"3557_CR59","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3233\/JAD-2012-120805","volume":"33","author":"T Del Ser","year":"2012","unstructured":"Del Ser T, Steinwachs KC, Gertz HJ, Andres MV, Gomez-Carrillo B, Medina M, et al. Treatment of Alzheimer\u2019s disease with the GSK-3 inhibitor tideglusib: a pilot study. J Alzheimers Dis. 2012;33:205\u201315.","journal-title":"J Alzheimers Dis"},{"key":"3557_CR60","doi-asserted-by":"publisher","first-page":"45937","DOI":"10.1074\/jbc.M306268200","volume":"278","author":"R Bhat","year":"2003","unstructured":"Bhat R, Xue Y, Berg S, Hellberg S, Orm\u00f6 M, Nilsson Y, et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol chem. 2003;278:45937\u201345.","journal-title":"J Biol chem"},{"key":"3557_CR61","doi-asserted-by":"publisher","first-page":"104159","DOI":"10.1016\/j.isci.2022.104159","volume":"25","author":"SM Law","year":"2022","unstructured":"Law SM, Zheng JJ. Premise and peril of Wnt signaling activation through GSK-3\u03b2 inhibition. iScience. 2022;25:104159.","journal-title":"iScience"},{"key":"3557_CR62","doi-asserted-by":"publisher","first-page":"588","DOI":"10.2337\/diabetes.52.3.588","volume":"52","author":"DB Ring","year":"2003","unstructured":"Ring DB, Johnson KW, Henriksen EJ, Nuss JM, Goff D, Kinnick TR, et al. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003;52:588\u201395.","journal-title":"Diabetes"},{"key":"3557_CR63","doi-asserted-by":"publisher","first-page":"792364","DOI":"10.3389\/fnmol.2021.792364","volume":"14","author":"SM Arciniegas Ruiz","year":"2022","unstructured":"Arciniegas Ruiz SM, Eldar-Finkelman H. Glycogen synthase kinase-3 inhibitors: preclinical and clinical focus on CNS-A decade onward. Front. Mol. Neurosci. 2022;14:792364.","journal-title":"Front. Mol. Neurosci"},{"key":"3557_CR64","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/35096019","volume":"2","author":"R Dhavan","year":"2001","unstructured":"Dhavan R, Tsai L-H. A decade of CDK5. Nat Rev Mol Cell Biol. 2001;2:749\u201359.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3557_CR65","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.molmed.2004.07.001","volume":"10","author":"JC Cruz","year":"2004","unstructured":"Cruz JC, Tsai L-H. Cdk5 deregulation in the pathogenesis of Alzheimer\u2019s disease. Trends Mol Med. 2004;10:452\u20138.","journal-title":"Trends Mol Med"},{"key":"3557_CR66","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/45159","volume":"402","author":"GN Patrick","year":"1999","unstructured":"Patrick GN, Zukerberg L, Nikolic M, de La Monte S, Dikkes P, Tsai L-H. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 1999;402:615\u201322.","journal-title":"Nature"},{"key":"3557_CR67","doi-asserted-by":"publisher","first-page":"6758","DOI":"10.1523\/JNEUROSCI.21-17-06758.2001","volume":"21","author":"J Ko","year":"2001","unstructured":"Ko J, Humbert S, Bronson RT, Takahashi S, Kulkarni AB, Li E, et al. p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment. J Neuroscie. 2001;21:6758\u201371.","journal-title":"J Neuroscie"},{"key":"3557_CR68","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/jnc.13365","volume":"136","author":"A Wilkaniec","year":"2016","unstructured":"Wilkaniec A, Czapski GA, Adamczyk AJ. Cdk5 at crossroads of protein oligomerization in neurodegenerative diseases: facts and hypotheses. J Neurochem. 2016;136:222\u201333.","journal-title":"J Neurochem"},{"key":"3557_CR69","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1111\/j.1471-4159.2008.05500.x","volume":"106","author":"A Asada","year":"2008","unstructured":"Asada A, Yamamoto N, Gohda M, Saito T, Hayashi N, Hisanaga S. Myristoylation of p39 and p35 is a determinant of cytoplasmic or nuclear localization of active cycline-dependent kinase 5 complexes. J Neurochem. 2008;106:1325\u201336.","journal-title":"J Neurochem"},{"key":"3557_CR70","first-page":"5124","volume":"125","author":"K-H Chang","year":"2012","unstructured":"Chang K-H, Vincent F, Shah K. Deregulated Cdk5 triggers aberrant activation of cell cycle kinases and phosphatases inducing neuronal death. J Cell Sci. 2012;125:5124\u201337.","journal-title":"J Cell Sci"},{"key":"3557_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109504","volume":"114","author":"W Yang","year":"2023","unstructured":"Yang W, Xu Q-Q, Yuan Q, Xian Y-F, Lin Z-X. Sulforaphene, a CDK5 Inhibitor, attenuates cognitive deficits in a transgenic mouse model of Alzheimer\u2019s disease via reducing A\u03b2 Deposition, tau hyperphosphorylation and synaptic dysfunction. Int Immunopharmacol. 2023;114:109504.","journal-title":"Int Immunopharmacol"},{"key":"3557_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-017-1027-y","volume":"15","author":"A Wilkaniec","year":"2018","unstructured":"Wilkaniec A, G\u0105ssowska-Dobrowolska M, Strawski M, Adamczyk A, Czapski G. Inhibition of cyclin-dependent kinase 5 affects early neuroinflammatory signalling in murine model of amyloid beta toxicity. J Neuroinflammation. 2018;15:1.","journal-title":"J Neuroinflammation"},{"key":"3557_CR73","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s10571-007-9224-3","volume":"27","author":"JP Lopes","year":"2007","unstructured":"Lopes JP, Oliveira CR, Agostinho PC. Role of cyclin-dependent kinase 5 in the neurodegenerative process triggered by amyloid-Beta and prion peptides: implications for Alzheimer\u2019s disease and prion-related encephalopathies. Cell Mol Neurobiol. 2007;27:943\u201357.","journal-title":"Cell Mol Neurobiol"},{"key":"3557_CR74","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00401-016-1662-x","volume":"133","author":"E Drummond","year":"2017","unstructured":"Drummond E, Wisniewski T. Alzheimer\u2019s disease: experimental models and reality. Acta Neuropathol. 2017;133:155\u201375.","journal-title":"Acta Neuropathol"},{"key":"3557_CR75","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1042\/BJ20070797","volume":"408","author":"J Bain","year":"2007","unstructured":"Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, Mclauchlan H, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007;408:297\u2013315.","journal-title":"Biochem J"},{"key":"3557_CR76","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.chembiol.2005.04.011","volume":"12","author":"ZA Knight","year":"2005","unstructured":"Knight ZA, Shokat KM. Features of selective kinase inhibitors. Chem Biol. 2005;12:621\u201337.","journal-title":"Chem Biol"},{"key":"3557_CR77","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","volume":"5","author":"MA Cannarile","year":"2017","unstructured":"Cannarile MA, Weisser M, Jacob W, Jegg A-M, Ries CH, R\u00fcttinger DJ. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer. 2017;5:53.","journal-title":"J Immunother Cancer"},{"key":"3557_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1602\/neurorx.2.1.1","volume":"2","author":"WM Pardridge","year":"2005","unstructured":"Pardridge WM. The blood-brain barrier and neurotherapeutics. NeuroRx. 2005;2:1.","journal-title":"NeuroRx"},{"key":"3557_CR79","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1146\/annurev.pharmtox.43.100901.140204","volume":"43","author":"A De Boer","year":"2003","unstructured":"De Boer A, Van der Sandt I, Gaillard P. The role of drug transporters at the blood-brain barrier. Annu Rev Pharmacol Toxicol. 2003;43:629\u201356.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"3557_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1440-1681.2000.03200.x","volume":"27","author":"G Halliday","year":"2000","unstructured":"Halliday G, Robinson SR, Shepherd C, Kril J. Alzheimer\u2019s disease and inflammation: a review of cellular and therapeutic mechanisms. Clin Exp Pharmacol Physiol. 2000;27:1\u20138.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"3557_CR81","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.2174\/0929867329666211221153719","volume":"29","author":"G Marotta","year":"2022","unstructured":"Marotta G, Basagni F, Rosini M, Minarini A. Role of Fyn kinase inhibitors in switching neuroinflammatory pathways. Curr Med Chem. 2022;29:4738\u201355.","journal-title":"Curr Med Chem"},{"key":"3557_CR82","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.3390\/ijms21124444","volume":"21","author":"C Matrone","year":"2020","unstructured":"Matrone C, Petrillo F, Nasso R, Ferretti G. Fyn tyrosine kinase as harmonizing factor in neuronal functions and dysfunctions. Int J Mol Sci. 2020;21:4444.","journal-title":"Int J Mol Sci"},{"key":"3557_CR83","doi-asserted-by":"publisher","first-page":"5986","DOI":"10.1007\/s12035-021-02518-3","volume":"58","author":"B Guglietti","year":"2021","unstructured":"Guglietti B, Sivasankar S, Mustafa S, Corrigan F, Collins-Praino LE. Fyn kinase activity and its role in neurodegenerative disease pathology: a potential universal target?. Mol Neurobiol. 2021;58:5986\u20136005.","journal-title":"Mol Neurobiol"},{"key":"3557_CR84","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/nn.3178","volume":"15","author":"JW Um","year":"2012","unstructured":"Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A, et al. Alzheimer amyloid-\u03b2 oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci. 2012;15:1227\u201335.","journal-title":"Nat Neurosci"},{"key":"3557_CR85","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s12035-024-04286-2","volume":"62","author":"S Meur","year":"2025","unstructured":"Meur S, Karati D. Fyn kinase in Alzheimer\u2019s disease: Unraveling molecular mechanisms and therapeutic implications. Mol Neurobiol. 2025;62:643\u201360.","journal-title":"Mol Neurobiol"},{"key":"3557_CR86","doi-asserted-by":"publisher","first-page":"9694","DOI":"10.1523\/JNEUROSCI.2980-05.2005","volume":"25","author":"J Chin","year":"2005","unstructured":"Chin J, Palop JJ, Puoliv\u00e4li J, Massaro C, Bien-Ly N, Gerstein H, et al. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer\u2019s disease. J Neurosci. 2005;25:9694\u2013703.","journal-title":"J Neurosci"},{"key":"3557_CR87","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.biopsych.2017.06.004","volume":"83","author":"HB Nygaard","year":"2018","unstructured":"Nygaard HB. Targeting Fyn kinase in Alzheimer\u2019s disease. Biol Psychiatry. 2018;83:369\u201376.","journal-title":"Biol Psychiatry"},{"key":"3557_CR88","first-page":"118","volume":"11","author":"G Du","year":"2020","unstructured":"Du G, Wang J, Zhang T, Ding Q, Jia X, Zhao X, et al. Targeting Src family kinase member Fyn by Saracatinib attenuated liver fibrosis in vitro and in vivo. CDDis. 2020;11:118.","journal-title":"CDDis"},{"key":"3557_CR89","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/ana.24394","volume":"77","author":"AC Kaufman","year":"2015","unstructured":"Kaufman AC, Salazar SV, Haas LT, Yang J, Kostylev MA, Jeng AT, et al. Fyn inhibition rescues established memory and synapse loss in A lzheimer mice. Ann Neurol. 2015;77:953\u201371.","journal-title":"Ann Neurol"},{"key":"3557_CR90","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1124\/jpet.111.187328","volume":"340","author":"X Sun","year":"2012","unstructured":"Sun X, Phan TN, Jung SH, Kim SY, Cho JU, Lee H, et al. LCB 03-0110, a novel pan-discoidin domain receptor\/c-Src family tyrosine kinase inhibitor, suppresses scar formation by inhibiting fibroblast and macrophage activation. J Pharmacol Exp Ther. 2012;340:510\u20139.","journal-title":"J Pharmacol Exp Ther"},{"key":"3557_CR91","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/bpa.12001","volume":"23","author":"H Lund","year":"2013","unstructured":"Lund H, Cowburn RF, Gustafsson E, Str\u00f6mberg K, Svensson A, Dahllund L, et al. Tau-Tubulin Kinase 1 expression, phosphorylation and Co-Localization with Phospho-S er422 Tau in the Alzheimer\u2019s disease brain. Brain Pathol. 2013;23:378\u201389.","journal-title":"Brain Pathol"},{"key":"3557_CR92","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fnmol.2014.00033","volume":"7","author":"S Ikezu","year":"2014","unstructured":"Ikezu S, Ikezu T. Tau-tubulin kinase. Front Mol Neurosci. 2014;7:33.","journal-title":"Front Mol Neurosci"},{"key":"3557_CR93","doi-asserted-by":"publisher","first-page":"9920","DOI":"10.1128\/MCB.25.22.9920-9935.2005","volume":"25","author":"Y Kawano","year":"2005","unstructured":"Kawano Y, Yoshimura T, Tsuboi D, Kawabata S, Kaneko-Kawano T, Shirataki H, et al. CRMP-2 is involved in kinesin-1-dependent transport of the Sra-1\/WAVE1 complex and axon formation. Mol Cell Biol. 2005;25:9920\u201335.","journal-title":"Mol Cell Biol"},{"key":"3557_CR94","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40478-020-0890-4","volume":"8","author":"S Ikezu","year":"2020","unstructured":"Ikezu S, Ingraham Dixie KL, Koro L, Watanabe T, Kaibuchi K, Ikezu T. Tau-tubulin kinase 1 and amyloid-\u03b2 peptide induce phosphorylation of collapsin response mediator protein-2 and enhance neurite degeneration in Alzheimer disease mouse models. Acta Neuropathol Commun. 2020;8:12.","journal-title":"Acta Neuropathol Commun"},{"key":"3557_CR95","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s40478-023-01661-3","volume":"11","author":"K Yukawa","year":"2023","unstructured":"Yukawa K, Yamamoto-Mcguire S, Cafaro L, Hong C, Kamme F, Ikezu T, et al. Antisense oligonucleotide-based targeting of Tau-tubulin kinase 1 prevents hippocampal accumulation of phosphorylated tau in PS19 tauopathy mice. Acta Neuropathol Commun. 2023;11:166.","journal-title":"Acta Neuropathol Commun"},{"key":"3557_CR96","doi-asserted-by":"publisher","first-page":"6358","DOI":"10.1021\/acs.jmedchem.1c00382","volume":"64","author":"T Halkina","year":"2021","unstructured":"Halkina T, Henderson JL, Lin EY, Himmelbauer MK, Jones JH, Nevalainen M, et al. Discovery of potent and brain-penetrant tau tubulin kinase 1 (TTBK1) inhibitors that lower tau phosphorylation in vivo. J Med Chem. 2021;64:6358\u201380.","journal-title":"J Med Chem"},{"key":"3557_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-32854-4","volume":"13","author":"FM Bashore","year":"2023","unstructured":"Bashore FM, Marquez AB, Chaikuad A, Howell S, Dunn AS, Beltran AA, et al. Modulation of tau tubulin kinases (TTBK1 and TTBK2) impacts ciliogenesis. Sci Rep. 2023;13:6118.","journal-title":"Sci Rep"},{"key":"3557_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2024.1352781","volume":"11","author":"RG Flax","year":"2024","unstructured":"Flax RG, Rosston P, Rocha C, Anderson B, Capener JL, Durcan TM, et al. Illumination of understudied ciliary kinases. Front Mol Biosci. 2024;11:1352781.","journal-title":"Front Mol Biosci"},{"key":"3557_CR99","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1107\/S2053230X14000144","volume":"70","author":"SE Kiefer","year":"2014","unstructured":"Kiefer SE, Chang CJ, Kimura SR, Gao M, Xie D, Zhang Y, et al. The structure of human tau-tubulin kinase 1 both in the apo form and in complex with an inhibitor. Acta Crystallogr F Struct Biol Commun. 2014;70:173\u201381.","journal-title":"Acta Crystallogr F Struct Biol Commun"},{"key":"3557_CR100","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3390\/ph17070952","volume":"17","author":"S Ahamad","year":"2024","unstructured":"Ahamad S, Junaid IT, Gupta D. Computational design of novel tau-tubulin kinase 1 inhibitors for neurodegenerative diseases. Pharmaceuticals (Basel). 2024;17:952.","journal-title":"Pharmaceuticals (Basel)"},{"key":"3557_CR101","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.neuron.2012.04.028","volume":"74","author":"JE Shin","year":"2012","unstructured":"Shin JE, Cho Y, Beirowski B, Milbrandt J, Cavalli V, DiAntonio A. Dual leucine zipper kinase is required for retrograde injury signaling and axonal regeneration. Neuron. 2012;74:1015\u201322.","journal-title":"Neuron"},{"key":"3557_CR102","doi-asserted-by":"publisher","first-page":"8078","DOI":"10.1021\/acs.jmedchem.8b00370","volume":"61","author":"M Siu","year":"2018","unstructured":"Siu M, Sengupta Ghosh A, Lewcock JW. Dual leucine zipper kinase inhibitors for the treatment of neurodegeneration: Miniperspective. J Med Chem. 2018;61:8078\u201387.","journal-title":"J Med Chem"},{"key":"3557_CR103","doi-asserted-by":"publisher","first-page":"e20725","DOI":"10.7554\/eLife.20725","volume":"6","author":"M Larhammar","year":"2017","unstructured":"Larhammar M, Huntwork-Rodriguez S, Jiang Z, Solanoy H, Sengupta Ghosh A, Wang B, et al. Dual leucine zipper kinase-dependent PERK activation contributes to neuronal degeneration following insult. Elife. 2017;6:e20725.","journal-title":"Elife"},{"key":"3557_CR104","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1073\/pnas.1211074110","volume":"110","author":"TA Watkins","year":"2013","unstructured":"Watkins TA, Wang B, Huntwork-Rodriguez S, Yang J, Jiang Z, Eastham-Anderson J, et al. DLK initiates a transcriptional program that couples apoptotic and regenerative responses to axonal injury. Proc Natl Acad Sci USA. 2013;110:4039\u201344.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3557_CR105","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag0394","volume":"9","author":"CE Le Pichon","year":"2017","unstructured":"Le Pichon CE, Meilandt WJ, Dominguez S, Solanoy H, Lin H, Ngu H, et al. Loss of dual leucine zipper kinase signaling is protective in animal models of neurodegenerative disease. Sci Transl Med. 2017;9:eaag0394.","journal-title":"Sci Transl Med"},{"key":"3557_CR106","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/mnfr.201100438","volume":"56","author":"HC Ku","year":"2012","unstructured":"Ku HC, Liu HS, Hung PF, Chen CL, Liu HC, Chang HH, et al. Green tea (-)-epigallocatechin gallate inhibits IGF-I and IGF-IIstimulation of 3T3-L1 preadipocyte mitogenesis via the 67-kDa laminin receptor, but not AMP-activated protein kinase pathway. Mol Nutr Food Res. 2012;56:580\u201392.","journal-title":"Mol Nutr Food Res"},{"key":"3557_CR107","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1021\/jm5013984","volume":"58","author":"S Patel","year":"2015","unstructured":"Patel S, Cohen F, Dean BJ, De La Torre K, Deshmukh G, Estrada AA, et al. Discovery of dual leucine zipper kinase (DLK, MAP3K12) inhibitors with activity in neurodegeneration models. J Med Chem. 2015;58:401\u201318.","journal-title":"J Med Chem"},{"key":"3557_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115404","volume":"255","author":"H Bu","year":"2023","unstructured":"Bu H, Li Z, Lu Y, Zhuang Z, Zhen Y, Zhang L. Deciphering the multifunctional role of dual leucine zipper kinase (DLK) and its therapeutic potential in disease. Eur J Med Chem. 2023;255:115404.","journal-title":"Eur J Med Chem"},{"key":"3557_CR109","doi-asserted-by":"publisher","first-page":"9954","DOI":"10.1021\/acs.jmedchem.3c00788","volume":"66","author":"K Le","year":"2023","unstructured":"Le K, Soth MJ, Cross JB, Liu G, Ray WJ, Ma J, et al. Discovery of IACS-52825, a potent and selective DLK inhibitor for treatment of chemotherapy-induced peripheral neuropathy. J Med Chem. 2023;66:9954\u201371.","journal-title":"J Med Chem"},{"key":"3557_CR110","first-page":"116","volume":"865","author":"K Yasojima","year":"2000","unstructured":"Yasojima K, Kuret J, DeMaggio AJ, McGeer E, McGeer PL. Casein kinase 1 delta mRNA is upregulated in Alzheimer disease brain. Brain Sci. 2000;865:116\u201320.","journal-title":"Brain Sci"},{"key":"3557_CR111","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1083\/jcb.201011111","volume":"192","author":"YE Greer","year":"2011","unstructured":"Greer YE, Rubin JS. Casein kinase 1 delta functions at the centrosome to mediate Wnt-3a\u2013dependent neurite outgrowth. J Cell Biol. 2011;192:993\u20131004.","journal-title":"J Cell Biol"},{"key":"3557_CR112","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.872171","volume":"9","author":"A Roth","year":"2022","unstructured":"Roth A, Sander A, Oswald MS, G\u00e4rtner F, Knippschild U, Bischof J. Comprehensive characterization of CK1\u03b4-mediated tau phosphorylation in Alzheimer\u2019s disease. Front Mol Biosci. 2022;9:872171.","journal-title":"Front Mol Biosci"},{"key":"3557_CR113","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0002-9440(10)65219-4","volume":"155","author":"N Ghoshal","year":"1999","unstructured":"Ghoshal N, Smiley JF, DeMaggio AJ, Hoekstra MF, Cochran EJ, Binder LI, et al. A new molecular link between the fibrillar and granulovacuolar lesions of Alzheimer\u2019s disease. Am J Pathol. 1999;155:1163\u201372.","journal-title":"Am J Pathol"},{"key":"3557_CR114","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1021\/acs.jproteome.9b00312","volume":"18","author":"P Adler","year":"2019","unstructured":"Adler P, Mayne J, Walker K, Ning Z, Figeys D. Therapeutic targeting of casein kinase 1\u03b4\/\u03b5 in an Alzheimer\u2019s disease mouse model. J Proteome Res. 2019;18:3383\u201393.","journal-title":"J Proteome Res"},{"key":"3557_CR115","doi-asserted-by":"publisher","first-page":"1094922.","DOI":"10.3389\/fmolb.2022.1094922","volume":"9","author":"A Venerando","year":"2022","unstructured":"Venerando A, Bustos VH, Pinna LA, Cozza G. Casein kinases in human diseases. Frontiers Media SA; Front Mol Biosci. 2022;9:1094922.","journal-title":"Frontiers Media SA; Front Mol Biosci"},{"key":"3557_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2024.106516","volume":"196","author":"VI Ko","year":"2024","unstructured":"Ko VI, Ong K, Cleveland DW, Yu H, Ravits JM. CK1\u03b4\/\u03b5 kinases regulate TDP-43 phosphorylation and are therapeutic targets for ALS-related TDP-43 hyperphosphorylation. Neurobiol Dis. 2024;196:106516.","journal-title":"Neurobiol Dis"},{"key":"3557_CR117","doi-asserted-by":"publisher","first-page":"4374","DOI":"10.1016\/j.bmcl.2013.05.075","volume":"23","author":"M Bibian","year":"2013","unstructured":"Bibian M, Rahaim RJ, Choi JY, Noguchi Y, Sch\u00fcrer S, Chen W, et al. Development of highly selective casein kinase 1\u03b4\/1\u03b5 (CK1\u03b4\/\u03b5) inhibitors with potent antiproliferative properties. Bioorg Med Chem Lett. 2013;23:4374\u201380.","journal-title":"Bioorg Med Chem Lett"},{"key":"3557_CR118","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00726-012-1234-x","volume":"43","author":"J Bischof","year":"2012","unstructured":"Bischof J, Leban J, Zaja M, Grothey A, Radunsky B, Othersen O, et al. 2-Benzamido-N-(1 H-benzo [d] imidazol-2-yl) thiazole-4-carboxamide derivatives as potent inhibitors of CK1\u03b4\/\u03b5. Amino Acids. 2012;43:1577\u201391.","journal-title":"Amino Acids"},{"key":"3557_CR119","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/hmg\/ddn326","volume":"18","author":"S Chatterjee","year":"2009","unstructured":"Chatterjee S, Sang T-K, Lawless GM, Jackson GR. Dissociation of tau toxicity and phosphorylation: role of GSK-3\u03b2, MARK and Cdk5 in a Drosophila model. Hum Mol Genet. 2009;18:164\u201377.","journal-title":"Hum Mol Genet"},{"key":"3557_CR120","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41392-025-02179-x","volume":"10","author":"X Wu","year":"2025","unstructured":"Wu X, Yang Z, Zou J, Gao H, Shao Z, Li C, et al. Protein kinases in neurodegenerative diseases: current understandings and implications for drug discovery. Signal Transduct Target Ther. 2025;10:146.","journal-title":"Signal Transduct Target Ther"},{"key":"3557_CR121","doi-asserted-by":"publisher","first-page":"136","DOI":"10.2165\/00002512-199506020-00006","volume":"6","author":"L-W Jin","year":"1995","unstructured":"Jin L-W, Saitoh T. Changes in protein kinases in Brain Aging and Alzheimer\u2019s Disease: implications for drug therapy. Drugs Aging. 1995;6:136\u201349.","journal-title":"Drugs Aging"},{"key":"3557_CR122","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.101173","volume":"13","author":"EM Ritchie","year":"2025","unstructured":"Ritchie EM, Acar D, Zhong S, Pu Q, Li Y, Zheng B, et al. Translatome analysis reveals cellular network in DLK-dependent hippocampal glutamatergic neuron degeneration. Elife. 2025;13:RP101173.","journal-title":"Elife"},{"key":"3557_CR123","first-page":"e58416","volume":"16","author":"S Thangwaritorn","year":"2024","unstructured":"Thangwaritorn S, Lee C, Metchikoff E, Razdan V, Ghafary S, Rivera D, et al. A review of recent advances in the management of Alzheimer\u2019s disease. Cureus. 2024;16:e58416.","journal-title":"Cureus"},{"key":"3557_CR124","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s41573-023-00774-7","volume":"22","author":"MW Mullowney","year":"2023","unstructured":"Mullowney MW, Duncan KR, Elsayed SS, Garg N, van der Hooft JJ, Martin NI, et al. Artificial intelligence for natural product drug discovery. Nat Rev Drug Discov. 2023;22:895\u2013916.","journal-title":"Nat Rev Drug Discov"},{"key":"3557_CR125","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1021\/acs.jmedchem.3c01093","volume":"67","author":"L Qin","year":"2024","unstructured":"Qin L, Cheng X, Wang S, Gong G, Su H, Huang H, et al. Discovery of novel aminobutanoic acid-based ASCT2 inhibitors for the treatment of non-small-cell lung cancer. J. Med. Chem. 2024;67:988\u20131007.","journal-title":"J. Med. Chem"},{"key":"3557_CR126","doi-asserted-by":"publisher","first-page":"4588","DOI":"10.1021\/acs.jmedchem.0c02044","volume":"64","author":"X Xu","year":"2021","unstructured":"Xu X, Wang J, Wang M, Yuan X, Li L, Zhang C, et al. Structure-enabled discovery of novel macrocyclic inhibitors targeting glutaminase 1 allosteric binding site. J. Med. Chem. 2021;64:4588\u2013611.","journal-title":"J. Med. Chem"},{"key":"3557_CR127","doi-asserted-by":"publisher","first-page":"17319","DOI":"10.1021\/acs.jmedchem.4c01223","volume":"67","author":"J Huang","year":"2024","unstructured":"Huang J, Su J, Wang H, Chen J, Tian Y, Zhang J, et al. Discovery of novel PROTAC SIRT6 degraders with potent efficacy against hepatocellular carcinoma. J. Med. Chem. 2024;67:17319\u201349.","journal-title":"J. Med. Chem"},{"key":"3557_CR128","doi-asserted-by":"publisher","first-page":"208","DOI":"10.5498\/wjp.v6.i2.208","volume":"6","author":"RB Khalil","year":"2016","unstructured":"Khalil RB, Khoury E, Koussa S. Linking multiple pathogenic pathways in Alzheimer\u2019s disease. World J Psychiatry. 2016;6:208.","journal-title":"World J Psychiatry"},{"key":"3557_CR129","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3390\/ph16091295","volume":"16","author":"SP Bhujbal","year":"2023","unstructured":"Bhujbal SP, Hah J-M. An innovative approach to address neurodegenerative diseases through kinase-targeted therapies: potential for designing covalent inhibitors. Pharmaceuticals (Basel). 2023;16:1295.","journal-title":"Pharmaceuticals (Basel)"},{"key":"3557_CR130","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1021\/acschemneuro.5c00508","volume":"16","author":"S Jaman","year":"2025","unstructured":"Jaman S, Tasmi SF, Shahriar I, Halim MA. Histidine focused covalent inhibitors targeting acetylcholinesterase: A computational pipeline for multisite therapeutic discovery in Alzheimer\u2019s disease. ACS Chem Neurosci. 2025;16:4025\u201336.","journal-title":"ACS Chem Neurosci"}],"container-title":["Medicinal Chemistry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-026-03557-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00044-026-03557-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-026-03557-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T12:04:06Z","timestamp":1777464246000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00044-026-03557-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":130,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["3557"],"URL":"https:\/\/doi.org\/10.1007\/s00044-026-03557-y","relation":{},"ISSN":["1054-2523","1554-8120"],"issn-type":[{"value":"1054-2523","type":"print"},{"value":"1554-8120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"9 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}